Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
It is almost ten years since the Banerjee 2009 report established that inappropriate prescribing of antipsychotics in the elderly was occurring in the UK and such patients had an 85% increased risk of adverse events and greater mortality. This report was a critical analysis addressing the outcomes of treatment practices for dementia in UK patients and globally, aimed at reducing prescribing of antipsychotic drugs for dementia. Since 2009, many significant studies worldwide (including several more recent large retrospective studies) provide more extensive longitudinal data for the adverse impacts of antipsychotic drugs in dementia. We have used the data in these studies including from over 380,000 dementia patients, with 85,069 prescribed antipsychotic agents as well as from 359,235 non-dementia antipsychotic drug users to provide an up-dated meta-analysis. This is the first meta-analysis to include evidence from general mental health studies showing that antipsychotic drugs precipitate excessive mortality across the spectrum. Prescribing of antipsychotic drugs for dementia or for other mental health care should be avoided and alternative means sought for handling behavioral disorders of such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Research has shown that antipsychotics are associated with an increased risk of stroke and death in individuals with dementia.56,57”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [56]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“About one‐quarter of people with dementia have problems sleeping, and the problems can worsen as the disease progresses.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Hunter, J., & Schmidt, F. (2004) · doi:10.4135/9781412985031 · Cited by 3,023
Fixed-and random-effects models in meta-analysis.
Hedges, L. V., & Vevea, J. L. (1998) · Psychological Methods · doi:10.1037/1082-989x.3.4.486 · Cited by 2,977 · cited 3×
“In addition, the Hedges and Vevea [31] as well as the Hunter and Schmidt [30] methods for calculating the pooled estimate from the 20 studies were compared, giving similar point effect sizes for the pooled HR, 2.”
MethodInfluentialPeters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 2×
“In 2005, based on the published greater risk of cerebrovascular events (with risperidone, olanzapine, and aripiprazole) from meta-analysis of 17 randomized placebo controlled trials, the Federal Food and Drug Administration (FDA) in the USA noted that such atypical antipsychotics were associated with a 60–70% increase…”
BackgroundResultEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 1×
“Worldwide, many similar studies over 2005–2009 were reported contraindicating use of antipsychotic drugs for dementia, with the majority clearly establishing and raising a serious red flag regarding their drug safety and adverse effects [9, 10, 12, 13, 20, 21].”
ResultAtypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194 · cited 7×
“This study compared those prescribed the atypical antipsychotics (risperidone (n = 4,406), olanzapine (n = 1,563), quetiapine (n = 497), and clozapine (n = 58) and 3,205 new users of conventional antipsychotics (haloperidol (n = 1,413), phenothiazines (including thioridazine [n = 546], perphenazine [n = 314], promazin…”
BackgroundResultInfluential
Research works printed but not linked: 1
- Banerjee S (2009) The use of antipsychotic medication for people with dementia: Time for action. Department of Health UK Government, London.
Cited by
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Postoperative delirium: perioperative assessment, risk reduction, and management
Jin, Z., Hu, J., & Ma, D. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.06.063 · Cited by 697
2025 Alzheimer's disease facts and figures
(2025) · Alzheimer's & Dementia · doi:10.1002/alz.70235 · Cited by 474
Kong, H., Xu, L., & Wang, D. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13873 · Cited by 199
Magierski, R., Sobow, T., Schwertner, E., & Religa, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01168 · Cited by 118
Postoperative delirium in geriatric patients with hip fractures
Chen, Y., Liang, S., Wu, H., Deng, S., Wang, F., Lunzhu, C., & Li, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1068278 · Cited by 131
“They reported that all three antipsychotics were associated with noticeably fewer days spent alive and out of the hospital, and similar results were also reported previously (Maust et al., 2015; Agar et al., 2017; Ralph and Espinet, 2018).”
ResultMok, P. L. H., Carr, M., Guthrie, B., Morales, D. R., Sheikh, A., Elliott, R. A., Camacho, E. M., van Staa, T. P., Avery, A. J., & Ashcroft, D. M. (2024) · BMJ · doi:10.1136/bmj-2023-076268 · Cited by 152
“11 12-14 The increased risks for stroke and mortality have been consistently reported by many observational studies and meta-analyses since, 11 15-21 and they have led to regulatory safety warnings and national interventions in the UK, US, and Europe, aiming to reduce inappropriate prescribing of…”
BackgroundRogowska, M., Thornton, M., Creese, B., Velayudhan, L., Aarsland, D., Ballard, C. G., Tsamakis, K., Stewart, R. J., & Mueller, C. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00992-5 · Cited by 122
“[36] also included information from European databases.”
BackgroundResultInfluentialDeprescribing as a Clinical Improvement Focus
Dharmarajan, T. S., Choi, H., Hossain, N., Munasinghe, U., Lakhi, F., Lourdusamy, D., Onuoha, S., Murakonda, P., Lebelt, A. S., Kanagala, M., et al. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.08.031 · Cited by 107
Overview of Meta-Analyses of Five Non-pharmacological Interventions for Alzheimer's Disease
Wang, L., Pei, J., Zhan, Y., & Cai, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.594432 · Cited by 94
“For example, some antipsychotics are associated with an increased risk of stroke and death in individuals with dementia (Maust et al., 2015; Ralph and Espinet, 2018).”
BackgroundBehavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics
Calsolaro, V., Femminella, G. D., Rogani, S., Esposito, S., Franchi, R., Okoye, C., Rengo, G., & Monzani, F. (2021) · Pharmaceuticals · doi:10.3390/ph14030246 · Cited by 89
“A recent meta-analysis including several large retrospective studies showed an increased all-cause mortality associated with antipsychotic use in patients with dementia [21].”
BackgroundThe Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease
Calsolaro, V., Antognoli, R., Okoye, C., & Monzani, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01465 · Cited by 70
Harrison, S. L., Cations, M., Jessop, T., Hilmer, S. N., Sawan, M. J., & Brodaty, H. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0623-6 · Cited by 66
Bipolar depression: a review of treatment options
Levenberg, K., & Cordner, Z. A. (2022) · General Psychiatry · doi:10.1136/gpsych-2022-100760 · Cited by 69
Siddappaji, K. K., & Gopal, S. (2021) · AIMS neuroscience · doi:10.3934/neuroscience.2021020 · Cited by 66
“When used in the long-term, they have been shown to associate with increased mortality [177].”
BackgroundThe antipsychotic medication, risperidone, causes global immunosuppression in healthy mice
May, M. A., Beauchemin, M., Vary, C., Barlow, D. J., & Houseknecht, K. L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218937 · Cited by 59
Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease
Heilman, K. M., & Nadeau, S. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01172-w · Cited by 64
“Mor‐ tality risk is highest in the first 6 months of use, it is dose related, and there is little difference in relative risk between atypical and typical antipsychotics [114].”
BackgroundDrug related problems in older adults living with dementia
Ruangritchankul, S., Peel, N. M., Hanjani, L. S., & Gray, L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236830 · Cited by 56
Definition and Measurement of Physical and Chemical Restraint in Long-Term Care: A Systematic Review
Robins, L., Lee, D. A., Bell, J. S., Srikanth, V. K., Möhler, R., Hill, K., & Haines, T. P. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073639 · Cited by 54
2026 Alzheimer's disease facts and figures
(2026) · Alzheimer s & Dementia · doi:10.1002/alz.71345 · Cited by 112
Crystal, S., Jarrin, O. F., Rosenthal, M., Hermida, R., & Angell, B. (2020) · Innovation in Aging · doi:10.1093/geroni/igaa018 · Cited by 45
“Persistently high use despite growing evidence of mortality led to calls for action (10,11).”
BackgroundWomen who suffer from schizophrenia: Critical issues
Seeman, M. V. (2018) · World Journal of Psychiatry · doi:10.5498/wjp.v8.i5.125 · Cited by 40
González-Rodríguez, A., Labad, J., & Seeman, M. V. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109941 · Cited by 41
Chenoweth, L., Jessop, T., Harrison, F., Cations, M., Cook, J. D., & Brodaty, H. (2018) · BioMed Research International · doi:10.1155/2018/7148515 · Cited by 43
“It was noted, however, that minimal reductions in behaviour incidence and severity was likely a positive outcome for these residents, given the proven iatrogenic adverse effects of psychotropics in dementia [7].”
BackgroundManaging Behavioral and Psychological Symptoms of Dementia (BPSD) in the Era of Boxed Warnings
Tampi, R. R., Bhattacharya, G., & Marpuri, P. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01347-y · Cited by 34
The Neuroinflammasome in Alzheimer’s Disease and Cerebral Stroke
Lee, J., Lee, C. J., Park, J., Lee, S. J., & Choi, S.-H. (2021) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000516074 · Cited by 29
Ralph, S. J., & Espinet, A. J. (2017) · Dementia · doi:10.1177/1471301217746769 · Cited by 29
Self-citationMasnoon, N., Ellett, L. M. K., Shakib, S., & Caughey, G. E. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00794-7 · Cited by 27
Psychotropic Drug Prescription in Nursing Homes During the COVID-19 Pandemic
Uriguen, A. F., Lucas, E. L., Sannino, C., Arrechea, I. I., Álaba, J., Echevarría, E., Goikouria, J. G., & Telleria, I. B. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00948-9 · Cited by 31
Management of Chronic Non-Cancer Pain: a Framework
Nadeau, S. E., & Lawhern, R. A. (2022) · Pain Management · doi:10.2217/pmt-2022-0017 · Cited by 27
Treating hallucinations in Parkinson’s disease
Powell, A., Matar, E., & Lewis, S. J. G. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1851198 · Cited by 25
“0) for patients with and without dementia [97].”
BackgroundCarvalho, A. F., Hsu, C.-W., Vieta, E., Solmi, M., Marx, W., Berk, M., Liang, C., Tseng, P., & Wang, L. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000535777 · Cited by 23
“As for other pharmacological interventions, evidence from other populations has shown that antipsychotics can increase risk of life-threatening medical comorbidities and death in persons with dementia [15], but they are associated with decreased mortality in people with schizophrenia [16].”
BackgroundBargagli, A. M., Cascini, S., Agabiti, N., Kirchmayer, U., Marino, C., & Davoli, M. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s218641 · Cited by 23
Zhang, C., Wang, L., Xu, Y., Huang, Y., Huang, J., Zhu, J., Wang, W., Li, W., Sun, A., Li, X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114347 · Cited by 21
Cullum, S. J., Varghese, C., Coomarasamy, C., Whittington, R., Hadfield, L., Rajay, A., Yeom, B. W., Liu, B., Christie, M., Appleton, K., et al. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5266 · Cited by 23
“It is well established that antipsychotics increase the risk of mortality in people with dementia.(30) The reason that this risk might be increased in Pacific Islanders and M aori may be due to their pre-existing increased risk of stroke and cardiovascular events;(8-10) however, these factors should be controlled for…”
BackgroundLayton, J. B., Forns, J., McQuay, L. J., Danysh, H. E., Dempsey, C., Anthony, M. S., & Turner, M. E. (2022) · Drug Safety · doi:10.1007/s40264-022-01260-6 · Cited by 20
“Previous studies have suggested an increased risk of mortality among users of antipsychotics during the initial 180 days of use [28] and potential differences in the risk between users of pimavanserin and users of other antipsychotics or untreated patients in the first 30, 90, or 180 days of treatment [17, 18].”
BackgroundCooper, R. E., Mason, J., Calton, T., Richardson, J. M., & Moncrieff, J. (2021) · Psychosis · doi:10.1080/17522439.2021.1930119 · Cited by 21
“There is an ongoing debate as to whether antipsychotics may increase or decrease overall mortality in people with schizophrenia, which is high compared to the general population (Ralph & Espinet, 2018; Taipale et al., 2018).”
ResultCascini, S., Agabiti, N., Marino, C., Acampora, A., Balducci, M. T., Calandrini, E., Davoli, M., & Bargagli, A. M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220369 · Cited by 19
“People with late-stage dementia and those residing in long-term care facilities represent the group most likely to receive a prescription for AP drugs [42].”
Wang, J., Shen, J. Y., Conwell, Y., Yu, F., Nathan, K., Heffner, K. L., Li, Y., & Caprio, T. V. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18555 · Cited by 19
“11 When used in patients living with ADRD, antipsychotic use can also cause confusion, memory loss, and reduce mobility and strength, 5 – 12 which may make it more challenging for one to improve in ADL function.”
BackgroundThe Effects of Antipsychotic Drugs and Non-Pharmacological Therapies on Schizophrenia
Nasim, R., Nawaz, S., & Nasim, T. (2025) · Targets · doi:10.3390/targets3010010 · Cited by 24
“Furthermore, investigating the underlying mechanisms of schizophrenia and the factors that contribute to treatment response can help identify novel therapeutic targets and improve treatment strategies [27].”
Viewpoint: do antipsychotics protect against early death? A critical view
Whitaker, R. B. (2020) · Psychological Medicine · doi:10.1017/s003329172000358x · Cited by 19
Li, X., Li, J., Huang, Y., Gong, Q., Fu, Y., Xu, Y., Huang, J., You, H., Zhang, D., Zhang, D., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114045 · Cited by 16
Death in Advance? A critique of the “Zombification” of people with dementia
Schweda, M., & Jongsma, K. R. (2022) · History & Philosophy of the Life Sciences · doi:10.1007/s40656-022-00512-z · Cited by 19
“As a consequence, they often have an increased risk of morbidity and mortality than older patients without cognitive impairments (Ralph & Espinet, 2018).”
BackgroundPostoperative delirium: identifying the patient at risk and altering the course
Hoogma, D. F., Milisen, K., Rex, S., & Tmimi, L. A. (2023) · European Journal of Anaesthesiology Intensive Care · doi:10.1097/ea9.0000000000000022 · Cited by 20
Melo, L., Pillai, A. A., Kompella, R., Patail, H., & Aronow, W. S. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2392002 · Cited by 18
“This elevated risk was observed with both typical and atypical antipsychotic agents [11].”
Kwon, C., & Lee, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713287 · Cited by 16
Oya, N., Ayani, N., Kuwahara, A., Kitaoka, R., Omichi, C., Sakuma, M., Morimoto, T., & Narumoto, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19053123 · Cited by 14
“For the assessment of ADEs, the reviewers were trained according to a review manual based on the previous methods [27].”
BackgroundInfluentialSuccinct Approach to Delirium in the Emergency Department
Lee, S., Angel, C., & Han, J. H. (2021) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-021-00226-9 · Cited by 13
Liau, S. J., Zhao, M., Hamada, S., Gutiérrez‐Valencia, M., Jadczak, A. D., Li, L., Martínez‐Velilla, N., Sakata, N., Fu, P., Visvanathan, R., et al. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.01.015 · Cited by 15
Edelstein, O. E., Wacht, O., Isralowitz, R., Reznik, A., & Bachner, Y. G. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102418 · Cited by 13
Potentially Inappropriate Medication Use in Community-Dwelling Older Adults Living with Dementia
Bae‐Shaaw, Y. H., Shier, V., Sood, N., Seabury, S. A., & Joyce, G. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221168 · Cited by 18
“Numerous studies reported about the dangers of using antipsychotics for treatment of behavioral symptoms related to dementia, demonstrating strong links between their uses and adverse events such as cognitive disturbances, cardio-and cerebrovascular events and increased mortality [15–18].”
Du, Y., Wolf, I.-K., Busch, M. A., & Knopf, H. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210695 · Cited by 17
Non-Pharmacological Interventions for Wandering/Aberrant Motor Behaviour in Patients with Dementia
Dimitriou, T., Papatriantafyllou, J. D., Konsta, A., Kazis, D. A., Athanasiadis, L., Ioannidis, P., Koutsouraki, E., Tegos, T. J., & Tsolaki, M. (2022) · Brain Sciences · doi:10.3390/brainsci12020130 · Cited by 14
Perreault, S., Boivin‐Proulx, L., Brouillette, J., Jarry, S., & Dorais, M. (2024) · Pharmaceuticals · doi:10.3390/ph17020178 · Cited by 16
Walsh, K. A., Byrne, S., McSharry, J., Browne, J. P., Irving, K., Hurley, E., Rochford-Brennan, H., Geoghegan, C., Presseau, J., & Timmons, S. (2021) · HRB Open Research · doi:10.12688/hrbopenres.13228.1 · Cited by 10
Clozapine Use in a Movement Disorder Clinic
Friedman, J. H., & Hershkowitz, D. (2022) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000510 · Cited by 12
Progress in mechanistically novel treatments for schizophrenia
Neef, J., & Palacios, D. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00096a · Cited by 10
Sečník, J., Eriksdotter, M., Xu, H., Annetorp, M., on behalf of the SweGeroCOVID Project, Rytarowski, A., Johnell, K., Hägg, S., & Religa, D. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01154-w · Cited by 11
“The mortality risk in antipsychotics depends on the agents prescribed and dosage [20, 50, 51], which could have further confounded the association.”
BackgroundNagata, K., Inoue, H., Yamashita, T., Akao, M., Atarashi, H., Ikeda, T., Koretsune, Y., Okumura, K., Shimizu, W., Suzuki, S. S., et al. (2023) · BMJ Neurology Open · doi:10.1136/bmjno-2022-000370 · Cited by 12
Italian guidance on Dementia Day Care Centres: A position paper
Mossello, E., Baccini, M., Caramelli, F., Biagini, C. A., Cester, A., Vreese, L. P. D., Darvo, G., Vampini, C., Gotti, M., Fabbo, A., et al. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02356-4 · Cited by 12
“The warning issued by the national and international regulatory authorities reports about an increased mortality rate in people with dementia treated with APs, with the risk being even higher with typical in comparison with atypical ones [94].”
BackgroundElvir-Lazo, O. L., White, P. F., Eng, H. C., Yumul, F., Chua, R., & Yumul, R. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1982297 · Cited by 12
“have been reported to increase the risk of all-cause mortality associated with dementia in older patients [105].”
BackgroundHealth Outcomes of Discontinuing Antipsychotics After Hospitalization in Older Adults
Yang, C., Wilkins, J. M., DiCesare, E., Pritchard, K. T., Chen, Q., Zhang, Y., Kim, D., & Lin, K. J. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0702 · Cited by 11
Managing the Behavioral and Psychological Symptoms of Dementia
Mendez, M. F. (2022) · Current Treatment Options in Neurology · doi:10.1007/s11940-022-00715-6 · Cited by 11
The Effect of Cannabidiol 3% on Neuropsychiatric Symptoms in Dementia – Six-Month Follow-Up
Alexandri, F., Papadopoulou, L., Tsolaki, A., Παπαντωνίου, Γ., Athanasiadis, L., & Tsolaki, M. (2023) · Clinical Gerontologist · doi:10.1080/07317115.2023.2209563 · Cited by 10
“However, in clinical practice, the management is more challenging, operating negatively for patients and caregivers (Bessey & Walaszek, 2019; Ralph & Espinet, 2018).”
Tan, T. C., Lau, E. C. Y., Le, T. H., Lu, C. Y., Hilmer, S. N., Jeon, Y., Low, L., & Tan, E. C. K. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01202-8 · Cited by 7
“Thus, previous studies [40–42] have suggested that typical antipsychotics should be reserved for situations that are considered to be an emergency and in the presence of delirium [43, 44].”
Aga, V. M. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.11.003 · Cited by 10
Palliative care for patients with advanced dementia
Navia, R. O., & Constantine, L. A. (2022) · Nursing · doi:10.1097/01.nurse.0000820024.83629.ee · Cited by 11
Fan, P., Zeng, L., Ding, Y., Kofler, J., Silverstein, J. C., Krivinko, J. M., Sweet, R. A., & Wang, L. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12979 · Cited by 8
Du, H., Wang, X., Lai, X., Wang, W., & Huo, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05962-2 · Cited by 14
“Elderly individuals, especially those with dementia, may be more sensitive to medication side effects, and cognitive decline can exacerbate these impacts [12].”
BackgroundOuslander, J. G. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19198 · Cited by 6
Stafford, A. C., Bender, S. M., Parsons, K., & Sung, B. (2024) · Australian Journal on Ageing · doi:10.1111/ajag.13294 · Cited by 6
Indicators of dementia disease progression in primary care: An electronic health record cohort study
Rathod‐Mistry, T., Marshall, M. B., Campbell, P., Bailey, J., Chew-Graham, C. A., Croft, P. R., Frisher, M., Hayward, R. A., Negi, R., Robinson, L. A., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14710 · Cited by 5
Gebauer, E.-M., & Lukas, A. (2022) · Biomedicines · doi:10.3390/biomedicines10123127 · Cited by 7
“In addition, there is an increased risk of all-cause mortality associated with antipsychotic use in older people with dementia [15] and side effects such as anticholinergic side effects [16],”
BackgroundKhalil, H., Hoppe, D., & Ameen, N. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986211012854 · Cited by 6
Walsh, K. A., Byrne, S., O'Riordan, A., McSharry, J., Browne, J. P., Irving, K., Hurley, E., & Timmons, S. (2022) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2022.100190 · Cited by 5
Parabiaghi, A., Compagnoni, M. M., D’Avanzo, B., Caggiu, G., Galbussera, A. A., Tettamanti, M., Fortino, I., & Barbato, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072073 · Cited by 7
The Prevalence of and Documented Indications for Antipsychotic Prescribing in Irish Nursing Homes
Kelleher, J. E., Weedle, P., & Donovan, M. D. (2021) · Pharmacy · doi:10.3390/pharmacy9040160 · Cited by 7
“adverse effects in people with dementia, including cardiovascular and metabolic effects, extrapyramidal symptoms, cognitive worsening, infections and falls [9,10,12].”
BackgroundFan, P., Kofler, J., Ding, Y., Marks, M., Sweet, R. A., & Wang, L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac394 · Cited by 8
Patterns and predictors of oral antipsychotic prescribing in adult patients with schizophrenia
Vadiei, N., El-Ali, J., Delaune, J., Wild, C., & Liu, Y. (2022) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2022.100148 · Cited by 8
What neurologists wish palliative care physicians knew
Vaughan, C. L., & Bruno, V. A. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85029-2.00005-1 · Cited by 4
Death Toll by Dementia DrugPreprint
Lee, J. (2021) · Research Square · doi:10.21203/rs.3.rs-384861/v4 · Cited by 4
“Deprescribing psychotropic medications are feasible for most people experiencing no withdrawal symptoms in long-term care 49,50 .”
BackgroundMondal, M., Solomon, S., Sun, J., Sampathkumar, N. K., Carre, I., Côtel, M.-C., Mehta, P. R., Rajendran, L., Vernon, A. C., Fang, F., et al. (2023) · medRxiv · doi:10.1101/2023.11.10.23298358 · Cited by 4
“A growing body of evidence demonstrates possible side effects of antipsychotics, including the increased risk of mortality in patients with dementia as well as in individuals without dementia (Ralph and Espinet, 2018).”
BackgroundReeve, E., Cowan, K., Ellett, L. M. K., Sinclair, R. G., Pietsch, A., Pietsch, T., de la Perrelle, L., Deimel, J., To, J., Daly, S., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251359984 · Cited by 4
Standal, K., Solbakken, O. A., Benth, J. Š., Abbass, A. A., & Heiervang, K. S. (2025) · International Journal of Social Psychiatry · doi:10.1177/00207640251390930 · Cited by 4
“…2018; Pfennig et al., 2013) and the justification for long-term pharmacological use (Alvarez-Jimenez et al., 2016; Baghai et al., 2012; Correll et al., 2018, 2022; Goff et al., 2017; Hengartner, 2020; Moncrieff et al., 2020; Ralph & Espinet, 2018; Smedslund et al., 2018; Suvisaari et al., 2018).”
Recent developments in geriatric psychopharmacology
Aftab, A., Lam, J. A., Liu, F., Ghosh, A., & Sajatovic, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1882848 · Cited by 4
“Antipsychotics as a class have been demonstrated as being effective in the treatment of NPS, but their efficacy is also recognized as being modest, with generally a small effect size [25,26].”
BackgroundInfluentialGonzález‐López, M. D. C., García-Ramón, M. J., Soriano, B. J. N., & Carreño, T. P. (2021) · Pharmaceuticals · doi:10.3390/ph14100997 · Cited by 3
Polymedikation und Neuroleptika in Schweizer Pflegeheimen in den Jahren 2019 und 2020
Giger, M., Anliker, M., & Bartelt, G. (2022) · Praxis · doi:10.1024/1661-8157/a003909 · Cited by 4
Characteristics of Music Therapy With Beneficial Impacts on Agitation in Dementia
Kristiansen, F. A., Stige, B., & Helle-Valle, A. (2023) · Voices A World Forum for Music Therapy · doi:10.15845/voices.v23i2.3851 · Cited by 5
“This practice is controversial due to severe side-effects (Maust et al., 2015; Ralph & Espinet, 2018).”
BackgroundDevelopment of the Gerontological Nursing Competency Questionnaire
Picella, D., & Woods, D. L. (2024) · Nursing Education Perspectives · doi:10.1097/01.nep.0000000000001254 · Cited by 3
Ntampakis, N., Diamantaras, K., Chouvarda, I., Tsolaki, M., Sarigianndis, P., & Argyriou, V. (2025) · Lecture notes in computer science · doi:10.1007/978-3-032-05185-1_40 · Cited by 7
Psychotropic Medication Use and Mortality in Long-Term Care Residents
Stones, M. J., Worobetz, S., Randle, J. M., Marchese, C., Fossum, S., Ostrom, D., & Brink, P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.85971 · Cited by 3
Herbal medicine for behavioral and psychological symptoms of dementia
Kwon, C.-Y., Lee, B., & Ha, D.-J. (2021) · Medicine · doi:10.1097/md.0000000000024577 · Cited by 3
Treatment Patterns With Antipsychotics in Long-Term Care Patients With Parkinson’s Disease Psychosis
Rashid, N., Shim, A., Andes, S., Quale, S., & Abler, V. (2021) · Journal of Applied Gerontology · doi:10.1177/0733464820987032 · Cited by 3
“This finding is a concern, given the association between AP use and increased morbidity and mortality in patients with dementia (Maust et al., 2015; Ralph & Espinet, 2018; Schneider et al., 2005).”
BackgroundNakamura, Z. M., Deal, A. M., Rosenstein, D. L., Quillen, L. J., Chien, S. A., Wood, W. A., Shea, T. C., & Park, E. M. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106076 · Cited by 3
Fernandes, J. V. A., Ramos, J. V. D. O., Vilar, L. A. D. S., & Holanda, M. M. D. A. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_197_25 · Cited by 3
“[13,49,50] While common TEAEs include somnolence and weight gain, the absence of significant differences in SAEs or Furthermore, when contextualizing brexpiprazole’s efficacy within the broader landscape of pharmacological interventions for agitation in Alzheimer’s disease, its effect size appears…”
White, J. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107058 · Cited by 2
“Associations with mortality may also arise through an increased susceptibility to illness caused directly by disadvantage in childhood (Lundberg, 1993), psychiatric medication shortening lifespan (Maslej et al., 2017; Ralph and Espinet, 2018), or a combination of these mechanisms.”
Background
Metadata
- Authors
- Ralph, S. J., & Espinet, A. J.
- Affiliations
- Griffith University (AU)
- Corresponding author
- Ralph, Stephen J.
- ORCID
- Ralph, Stephen J.
- Venue
- Journal of Alzheimer's Disease Reports
- Publisher
- SAGE Publications
- Published
- 2018-02-02
- Volume
- 2
- Issue
- 1
- Pages
- 1-26
- ISSN
- 2542-4823 (ISSN-L)
- PMC
- PMC6159703
- OpenAlex
- W2786890905
- Cited by
- 160
- References
- 93
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 21 · 2023: 21 · 2022: 35 · 2021: 26 · 2020: 17 · 2019: 10 · 2018: 6
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (unspecified)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease Reports (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Griffith Research Online (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- antipsychotic drugs, all-cause mortality, dementia, inappropriate prescribing, elderly patients, behavioral and psychological symptoms of dementia, adverse drug reactions, prescribing patterns
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.